The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) is also attempting to use canakinumab (a monoclonal anti-IL-1β antibody) to evaluate the inflammatory hypothesis of cardiovascular disease, as well as the critical role of IL-1β-mediated inflammation in the development of cardiovascular diseases, including CHD [24]. Here, IL1B is linked to cardiovascular disorder.